Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://www.ncbi.nlm.nih.gov/pubmed/25377907
http://dx.doi.org/10.1007/s00223-014-9927-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://www.ncbi.nlm.nih.gov/pubmed/25377907
http://dx.doi.org/10.1007/s00223-014-9927-7

Ejemplares similares